文献速递自身炎症与 IgG4 相关病

Canakinumab治疗成人Still病以减少关节炎表现(CONSIDER):II期随机双盲安慰剂对照多中心研究者发起试验

Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial.
PubMed 文献 · Ann Rheum Dis · 2020-05-13

该II期随机双盲安慰剂对照多中心试验评估canakinumab在成人Still病(AOSD)伴活动性关节受累患者中的疗效与安全性。主要终点(第12周ΔDAS28>1.2的患者比例)未达到统计学显著(67% vs 41%,p=0.18),但符合方案分析中canakinumab组ACR30/50/70缓解率显著更高。研究提前终止,安全性总体与已知特征一致,数据支持IL-1抑制用于AOSD。

要点

  • 主要终点ΔDAS28>1.2比例在canakinumab组67%、安慰剂组41%,差异未达统计学显著(p=0.18)。
  • 符合方案分析中canakinumab组ACR30(61% vs 20%,p=0.033)、ACR50(50% vs 6.7%,p=0.009)、ACR70(28% vs 0%,p=0.049)均显著优于安慰剂。
  • canakinumab组2例发生严重不良事件,总体安全性与该药已知特征一致。

核心结论

  • 尽管研究提前终止且主要终点未达到,canakinumab治疗使AOSD多项结局指标改善,数据支持IL-1抑制用于AOSD。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照、研究者发起的II期试验,纳入伴活动性关节受累(压痛和肿胀关节计数各≥4)的AOSD患者。
  • canakinumab组给予4 mg/kg(最大300 mg)皮下注射每4周一次,对照组给予安慰剂。
  • 主要终点为第12周疾病活动度评分变化(ΔDAS28>1.2)的患者比例。

主要发现

  • 入组时canakinumab组平均DAS28(ESR)为5.4,安慰剂组为5.3。
  • 意向性治疗分析中,canakinumab组12例(67%)、安慰剂组7例(41%)达到主要终点(p=0.18)。
  • 符合方案分析中,canakinumab组ACR30缓解率为61% vs 安慰剂组20%(p=0.033)。
  • 符合方案分析中,canakinumab组ACR50缓解率为50% vs 安慰剂组6.7%(p=0.009)。
  • 符合方案分析中,canakinumab组ACR70缓解率为28% vs 安慰剂组0%(p=0.049)。

关键数值与推荐

  • 主要终点定义为第12周ΔDAS28>1.2的患者比例。
  • canakinumab剂量为4 mg/kg(最大300 mg)皮下注射每4周一次。
  • 入组要求压痛关节计数和肿胀关节计数各≥4。

临床怎么用

  • 对于伴活动性关节受累的AOSD患者,canakinumab可改善ACR缓解率,但主要终点未达统计学显著,需结合个体情况权衡使用。
  • 治疗期间应监测严重不良事件,本试验中canakinumab组有2例发生严重不良事件。

局限性

  • 研究提前终止,可能影响统计效能和结论的稳健性。
  • 主要终点未达到统计学显著差异。
  • 样本量较小,意向性治疗分析中canakinumab组12例、安慰剂组7例达到主要终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inhibition of interleukin (IL)-1 represents a promising treatment option in adult-onset Still's disease (AOSD). OBJECTIVE: To investigate the efficacy and safety of canakinumab in patients with AOSD and active joint involvement by means of a multicentre, double-blind, randomised, placebo-controlled trial. METHODS: Patients with AOSD and active joint involvement (tender and swollen joint counts of ≥4 each) were treated with canakinumab (4 mg/kg, maximum 300 mg subcutaneous every 4 weeks) or placebo. The primary endpoint was the proportion of patients with a clinically relevant reduction in disease activity at week 12 as determined by the change in disease activity score (ΔDAS28>1.2). RESULTS: At enrolment, patients had high active disease with a mean DAS28(ESR) of 5.4 in the canakinumab and 5.3 in the placebo group, respectively. In the intention-to-treat analysis, 12 patients (67%) in the canakinumab group and 7 patients (41%) in the placebo group fulfilled the primary outcome criterion (p=0.18). In the per-protocol analysis, significantly higher American College of Rheumatology (ACR) 30% (61% vs 20%, p=0.033), ACR 50% (50% vs 6.7%, p=0.009) and ACR 70% (28% vs 0%, p=0.049) response rates were observed in the canakinumab group compared with the placebo group. Two patients in the canakinumab group experienced a serious adverse event. CONCLUSION: Although the study was terminated prematurely and the primary endpoint was not achieved, treatment with canakinumab led to an improvement of several outcome measures in AOSD. The overall safety findings were consistent with the known profile of canakinumab. Thus, our data support indication for IL-1 inhibition with canakinumab in AOSD.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Kedor C, Listing J, Zernicke J, et al. Canakinumab for Treatment of Adult-Onset Still's Disease to Achieve Reduction of Arthritic Manifestation (CONSIDER): phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis. 2020. PMID: 32404342. doi:10.1136/annrheumdis-2020-217155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。